Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01053936 · ClinicalTrials.gov registry record · Phase 2
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT01053936 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 129 participants.
The verdict
NCT01053936, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
This study assesses the effects of a new formulation of bardoxolone methyl on eGFR in Patients with Chronic Kidney Disease and Type 2 Diabetes.
Interventions
- DRUG Bardoxolone methyl (amorphous dispersion)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2010-01-31 |
| Est. Completion | 2011-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01053936
The ClinicalTrials.gov registry entry for NCT01053936 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bardoxolone methyl (amorphous dispersion) is the first listed.
NCT01053936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01053936 about?
NCT01053936 is a clinical study titled "Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease". This study assesses the effects of a new formulation of bardoxolone methyl on eGFR in Patients with Chronic Kidney Disease and Type 2 Diabetes.
What is the current status of trial NCT01053936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2010-01-31. Estimated completion is 2011-02-28.
What interventions are being tested in trial NCT01053936?
The interventions under investigation include: Bardoxolone methyl (amorphous dispersion) (DRUG).
Who is sponsoring clinical trial NCT01053936?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.